Tumor Embolization Devices Market Report 2026

Tumor Embolization Devices Market Overview

• Tumor Embolization Devices market size has reached to $1587.48 billion in 2025 • Expected to grow to $2464.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Tumor Embolization Devices Market Growth Fueled By Rising Cancer Incidence • Market Trend: Innovative Medication Advancements In The Tumor Embolization Devices Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tumor Embolization Devices Market?

Tumor embolization devices are minimally invasive devices used in the treatment of tumors. These devices are used either to shut down the supply of blood to the tumor or to deliver tumor-killing therapy directly to the tumor. The main types of tumor embolization devices are radioembolic agents and non-radioactive embolic agents. Non-radioactive embolic agents involve gelatin foam, tris-acryl gelatin microspheres, and polyvinyl alcohol (PVA) used in the treatment of tumors. The applications involved are cancer tumors and noncancerous tumors that are used by various end-users such as hospitals, cancer treatment centers, intensive care units, and surgical centers.

What Is The Tumor Embolization Devices Market Growth Forecast?

The tumor embolization devices market size is expected to see strong growth in the next few years. It will grow to $2464.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing investments in interventional oncology, rising demand for combination cancer therapies, expansion of targeted drug delivery techniques, growing focus on organ-sparing treatments, increasing integration of imaging-guided interventions. Major trends in the forecast period include increasing adoption of targeted embolization therapies, rising demand for drug-eluting embolic agents, growing use of image-guided embolization procedures, expansion of minimally invasive oncology interventions, enhanced focus on precision tumor targeting.

Global Tumor Embolization Devices Market Segmentation

1) By Type: Radioembolic Agents, Non-radioactive Embolic Agents 2) By Application: Cancer Tumors, Noncancerous Tumors 3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, Surgical Centers Subsegments: 1) By Radioembolic Agents: Yttrium-90 (Y-90) Microspheres, Holmium-166 Microspheres 2) By Non-radioactive Embolic Agents: Drug-Eluting Beads (DEBs), Microspheres (Polyvinyl Alcohol - PVA Particles), Gelatin Sponges, Liquid Embolic Agents (Onyx, Glue-Based Agents)

What Are The Drivers Of The Tumor Embolization Devices Market?

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the tumor embolization devices market during the forecast period. Cancer is a disease where abnormal cells grow uncontrollably and can invade or spread to other parts of the body. The increase in cancer cases is driven by aging populations, as older individuals are at higher risk of developing cancer due to accumulated genetic mutations and longer exposure to risk factors. Tumor embolization devices help address the rise in cancer cases by providing targeted, minimally invasive treatment that blocks blood flow to tumors, effectively slowing their growth and improving patient outcomes.For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1,958,310 new cancer cases are diagnosed in the US, an increase compared to more than 1,918,030 new cancer cases in 2022. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the tumor embolization market over the forthcoming years. The growth in healthcare expenditures is poised to propel the tumor embolization devices market forward. Healthcare expenditures encompass all costs associated with delivering healthcare services, including family planning, nutrition programs, and emergency assistance with a focus on health. Increased healthcare spending supports the development of various health-related products, including tumor embolization devices. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Consequently, the rise in healthcare expenditures is a driving force behind the tumor embolization devices industry's growth.

Key Players In The Global Tumor Embolization Devices Market

Major companies operating in the tumor embolization devices market are Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., Varian Medical Systems Inc.

Global Tumor Embolization Devices Market Trends and Insights

Major companies operating in the tumor embolization devices market are increasing their focus on introducing novel medications, such as Eye90, to maximize revenue in the market. Eye90 microspheres are a Y90 radioembolization device designed for the treatment of liver tumors, specifically hepatocellular carcinoma. For instance, in May 2023, ABK Biomedical, a Canada-based medical device company, received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to commence a multicenter pivotal study of Eye90 microspheres in hepatocellular carcinoma. Eye90 microspheres are a novel technology for Y90 radioembolization made with a proprietary manufacturing process that produces microspheres with a uniform size distribution and high radioactivity concentration. The microspheres are designed to deliver a high dose of radiation to the tumor while minimizing exposure to healthy tissue.

Regional Outlook

North America was the largest region in the tumor embolization devices market in 2025. Asia-Pacific was the second largest region in the tumor embolization devices market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Tumor Embolization Devices Market?

The tumor embolization devices market consists of sales of radioembolic agents and non-radioactive embolic agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.